Ms. Susan Benton is a strategic business consultant and owner of i2eye Consulting, LLC. Since July 2024, she has been a strategic advisor and consultant to six ophthalmic start-up companies. In addition to consulting, she joined the Ocuphire (now Opus) Board in November 2020, and she also sits on the boards of Tarsier Pharma since March 2019, and Omma Therapeutics since July 2024. Ms. Benton was previously a Member of the Board at Ripple Therapeutics. Ms. Benton has more than 30 years of experience in the pharmaceutical and biotech industry. For the past five years, Ms. Benton served as the CEO/President of Thea Pharma U.S. from July 2019 to July 2024 and built the business from scratch to a $100M business through the acquisition of products and the successful approval/ launch of the IYUZEH® and IVIZIA® brands. Prior to Thea, Ms. Benton served at the Global Commercial Lead for new ophthalmic products and ran the Innovation team responsible for early-stage research pipeline. Additionally, she was the Head of M&A for Shire where she built the early and mid-stage pipeline prior to the Takeda acquisition. Her ophthalmic career also includes executive leadership roles at B+L and Sirion Therapeutics. Susan holds an MBA from the University of South Florida and a Bachelor of Science degree in Biology from Muhlenberg College.
Susan Benton, MBA
